Question 1

What is DRMA's ST Score?

Accepted Answer

Dermata Therapeutics, Inc. (DRMA) has an ST Score of 45.0 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Question 2

Is DRMA a buy, hold, or sell?

Accepted Answer

Analysts rate DRMA a Buy, with a price target of $6.00 (+412.8% vs the current price). Our ST Score grades it C+ (45.0/100). The ST Score is a data-driven signal, not a recommendation.

Question 3

What are DRMA's factor grades?

Accepted Answer

Valuation C+, Profitability F, Financial Strength C+, Momentum C-, Growth A+, Forecast A.

Question 4

What is DRMA's valuation grade?

Accepted Answer

Dermata Therapeutics, Inc. (DRMA) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Question 5

What is DRMA's growth grade?

Accepted Answer

Dermata Therapeutics, Inc. (DRMA) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Question 6

What is DRMA's profitability grade?

Accepted Answer

Dermata Therapeutics, Inc. (DRMA) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Question 7

What is DRMA's financial strength grade?

Accepted Answer

Dermata Therapeutics, Inc. (DRMA) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

Question 8

What is the analyst price target for DRMA?

Accepted Answer

The average analyst price target for Dermata Therapeutics, Inc. (DRMA) is $6.00 from 1 analysts, which is +412.8% versus the recent price of $1.17.

Question 9

What is DRMA's Piotroski score?

Accepted Answer

Dermata Therapeutics, Inc. (DRMA) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.

Dermata Therapeutics, Inc. (DRMA) Financials — Income, Balance Sheet & Cash Flow

How do I analyze Dermata Therapeutics, Inc.'s financial statements?

Where can I find DRMA's revenue and earnings history?

What are the key financial ratios for DRMA?

Why are DRMA's financials important?

What is the current Dermata Therapeutics, Inc. (DRMA) stock price?

What sector and industry does DRMA operate in?

What is DRMA's market cap?

How many employees does DRMA have?